Merck KGaA multiple sclerosis drug fails in late-stage trials Ruchika Sharma7 Dec 2023 3:30 PM ISTFrankfurt: Merck KGaA's experimental multiple sclerosis (MS) drug missed the primary goal in highly anticipated late-stage trials, dealing a...
USFDA pauses initiation of new patients on multiple sclerosis evobrutinib drug: Merck Ruchika Sharma15 April 2023 11:19 AM ISTThe company must now place on hold the initiation of new evobrutinib patients and halt studies involving patients who have been taking the drug for...
IQVIA gets CDSCO panel okay to reopen trial recruitment in the country for Evobrutinib Dr. Divya Colin26 Oct 2022 1:30 PM ISTNew Delhi: Approving IQVIA proposal to amend Phase III Clinical Trail protocol of Bruton's tyrosine kinase (BTK) inhibitor Evobrutinib, the Subject...
Merck completes enrolment of Evobrutinib Phase III Trials ahead of ECTRIMS 2021 Ruchika Sharma5 Oct 2021 10:00 AM ISTDarmstadt: Merck, a science and technology company, has recently announced enrolment has been completed in the Phase III EVOLUTION RMS clinical trial...
